Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Sartorius Stedim Biotech S.A.
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-98.6% vs price
Base Case (Median)
-97.2% vs price
Bull Case (75th pct.)
-96.6% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $0.30 | -98.6% | High (40%) |
| PE Comparable | $0.79 | -96.5% | Medium (25%) |
| Growth Trajectory DCF | $0.88 | -96.1% | Medium (20%) |
| Graham Number | $0.62 | -97.2% | Medium (40%) |
| EV/EBITDA | $0.74 | -96.7% | Medium (20%) |
| EV/FCF | $0.31 | -98.6% | Medium (20%) |
| Earnings Power Value | $0.27 | -98.8% | Medium (50%) |
Based on 7 out of 7 methods, SRTOY appears overvalued at the current price of $22.36. The base case fair value of $0.62 implies 97.2% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.